Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-390MR maintenance of healed erosive esophagitis study
2005-001189-15Phase 3Completed
- Sponsor
- TAP Pharmaceutical Products
- Start
- Dec 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dexlansoprazole in erosive esophagitis (EE) (3 arms), sponsored by TAP Pharmaceutical Products. Primary endpoint: Maintenance of complete healing of erosive esophagitis. Started Dec 2005; status: completed.
02
Drugs
dexlansoprazole
03
Conditions
erosive esophagitis (EE)
Beyond the preview
Go deeper on 2005-001189-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001189-15.